SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?


To: Chuca Marsh who wrote (1280)8/18/1999 7:53:00 PM
From: Sean Janzen  Read Replies (1) | Respond to of 1501
 
I wonder what's happening with IZP's drug pipeline these days.

Remember this paragraph from the May 28 /97 news release.

Inflazyme Pharmaceuticals Ltd. is an emerging biopharmaceutical company specializing in the discovery, design and commercialization of novel generations of drugs which combat major inflammatory diseases, such as asthma, allergies, arthritis, psoriasis and a number of other illnesses categorized as inflammatory diseases. Inflazyme¡s current drugs in development are Apanol TM for asthma, Tiesole TM for allergies, Bispan TM for rheumatoid arthritis, Sortac TM for psoriasis, IZP-96002 for inflammatory bowel disease, IZP-96005 for pulmonary edema and IZP-97001 for reperfusion injury.